Symbols / VRCA $6.26 +1.46%
VRCA Chart
About
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 107.54M |
| Enterprise Value | 77.48M | Income | -17.89M | Sales | 35.58M |
| Book/sh | 1.44 | Cash/sh | 1.75 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -3.65 | PEG | — |
| P/S | 3.02 | P/B | 4.35 | P/C | — |
| EV/EBITDA | -6.76 | EV/Sales | 2.18 | Quick Ratio | 2.16 |
| Current Ratio | 2.59 | Debt/Eq | 6.59 | LT Debt/Eq | — |
| EPS (ttm) | -1.68 | EPS next Y | -1.72 | EPS Growth | — |
| Revenue Growth | 13.80% | Earnings | 2026-05-13 | ROA | -14.74% |
| ROE | -240.36% | ROIC | — | Gross Margin | 65.44% |
| Oper. Margin | -136.41% | Profit Margin | -50.27% | Shs Outstand | 17.18M |
| Shs Float | 6.78M | Short Float | 3.41% | Short Ratio | 3.15 |
| Short Interest | — | 52W High | 9.82 | 52W Low | 3.28 |
| Beta | 1.46 | Avg Volume | 155.80K | Volume | 85.84K |
| Target Price | $16.50 | Recom | Strong_buy | Prev Close | $6.17 |
| Price | $6.26 | Change | 1.46% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$16.50
Mean price target
2. Current target
$6.31
Latest analyst target
3. DCF / Fair value
$-16.20
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.31
Low
$10.00
High
$20.00
Mean
$16.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-18 | up | Brookline Capital | Hold → Buy | $17 |
| 2025-05-14 | reit | Needham | Hold → Hold | — |
| 2025-04-09 | reit | Needham | Hold → Hold | — |
| 2025-04-08 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-03-12 | reit | Needham | Hold → Hold | — |
| 2024-12-20 | reit | Needham | Hold → Hold | — |
| 2024-11-06 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-11-05 | reit | Needham | — → Hold | — |
| 2024-11-05 | down | RBC Capital | Outperform → Sector Perform | $2 |
| 2024-10-21 | main | TD Cowen | Buy → Buy | $10 |
| 2024-10-04 | main | RBC Capital | Outperform → Outperform | $11 |
| 2024-10-03 | down | Needham | Buy → Hold | $12 |
| 2024-10-02 | down | Brookline Capital | Buy → Hold | — |
| 2024-08-15 | main | RBC Capital | Outperform → Outperform | $13 |
| 2024-08-15 | main | Needham | Buy → Buy | $12 |
| 2024-05-16 | reit | Needham | Buy → Buy | $16 |
| 2024-05-14 | main | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-05-14 | main | Needham | Buy → Buy | $16 |
| 2024-04-10 | reit | Needham | Buy → Buy | $8 |
| 2024-03-01 | reit | Needham | Buy → Buy | $8 |
- VERRICA PHARMACEUTICAL ($VRCA) Releases Q4 2025 Earnings - Quiver Quantitative Wed, 11 Mar 2026 12
- Verrica schedules March 11 call on 2025 results and skin drug business - Stock Titan hu, 05 Mar 2026 08
- The Technical Signals Behind (VRCA) That Institutions Follow - Stock Traders Daily Mon, 16 Mar 2026 00
- Highs Report: How liquid is VRCA stock - 2026 Price Targets & Daily Entry Point Alerts - baoquankhu1.vn ue, 17 Mar 2026 17
- How Much Upside is Left in Verrica Pharmaceuticals (VRCA)? Wall Street Analysts Think 97.11% - Yahoo Finance Mon, 12 Jan 2026 08
- Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR) - The Globe and Mail hu, 12 Mar 2026 19
- Verrica Pharmaceuticals Q4 Loss Reignites Debate On Path To Sustainable Profitability - simplywall.st hu, 12 Mar 2026 23
- Verrica Pharmaceuticals (NASDAQ:VRCA) Announces Quarterly Earnings Results - MarketBeat Wed, 11 Mar 2026 13
- Verrica Pharmaceuticals Stock 5-Day Winning Spree: Stock Climbs 88% - Trefis ue, 02 Dec 2025 08
- Verrica stock surges after positive EMA feedback on molluscum treatment - Investing.com Mon, 20 Oct 2025 07
- Verrica Pharmaceuticals Stock (VRCA) Opinions on $50 Million Financing Deal | VRCA Stock News - Quiver Quantitative Sun, 30 Nov 2025 08
- New wart treatment enters Phase 3 testing for 22M U.S. patients - Stock Titan Wed, 07 Jan 2026 08
- Verrica Pharmaceuticals Inc (VRCA) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance Mon, 11 Aug 2025 07
- $VRCA stock is down 9% today. Here's what we see in our data. - Quiver Quantitative ue, 06 Jan 2026 08
- Verrica (NASDAQ: VRCA) Announces $50M PIPE to Retire OrbiMed Debt, Extend Runway to 2027 - Stock Titan Mon, 24 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 10000 | — | — | Stock Award(Grant) at price 0.00 per share. | KIRBY JOHN J. | Chief Financial Officer | — | 2025-12-23 00:00:00 | D |
| 1 | 4126142 | 17505157 | — | Purchase at price 4.24 per share. | MANNING PAUL B. | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-25 00:00:00 | D/I |
| 2 | 3536 | 15001 | — | Purchase at price 4.24 per share. | KIRBY JOHN J. | Chief Financial Officer | — | 2025-11-25 00:00:00 | D |
| 3 | 2357 | 10000 | — | Purchase at price 4.24 per share. | ROSENBERG NOAH L | Officer | — | 2025-11-25 00:00:00 | D |
| 4 | 94311 | 400114 | — | Purchase at price 4.24 per share. | RIEGER JAYSON | Chief Executive Officer | — | 2025-11-25 00:00:00 | D |
| 5 | 10000 | 42425 | — | Purchase at price 4.24 per share. | ZAWITZ DAVID | Chief Operating Officer | — | 2025-11-25 00:00:00 | D |
| 6 | 4315 | 2805 | — | Sale at price 0.65 per share. | HAYES CHRISTOPHER G | Officer | — | 2025-03-17 00:00:00 | D |
| 7 | 450000 | — | — | Stock Gift at price 0.00 per share. | MANNING PAUL B. | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-11-26 00:00:00 | D |
| 8 | 22921348 | 22795281 | — | Purchase at price 0.99 per share. | MANNING PAUL B. | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-11-22 00:00:00 | D/I |
| 9 | 1123595 | 1117415 | — | Purchase at price 0.99 per share. | STALFORT JOHN A | Director | — | 2024-11-22 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -10.23M | -63.17M | -59.66M | -20.16M |
| TotalUnusualItems | 869.00K | -2.73M | -2.54M | -1.44M |
| TotalUnusualItemsExcludingGoodwill | 869.00K | -2.73M | -2.54M | -1.44M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -17.89M | -76.58M | -67.00M | -24.49M |
| ReconciledDepreciation | 781.00K | 1.27M | 836.00K | 718.00K |
| ReconciledCostOfRevenue | 3.44M | 2.74M | 746.00K | 725.00K |
| EBITDA | -9.36M | -65.90M | -62.20M | -21.60M |
| EBIT | -10.14M | -67.17M | -63.03M | -22.32M |
| NetInterestIncome | -6.81M | -8.00M | -1.22M | -1.70M |
| InterestExpense | 7.74M | 9.41M | 3.96M | 2.17M |
| InterestIncome | 929.00K | 1.42M | 2.74M | 476.00K |
| NormalizedIncome | -18.75M | -73.85M | -64.46M | -23.05M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -17.89M | -76.58M | -67.00M | -24.49M |
| TotalExpenses | 47.52M | 73.40M | 68.35M | 30.33M |
| TotalOperatingIncomeAsReported | -12.19M | -65.92M | -65.76M | -21.30M |
| DilutedAverageShares | 5.18M | 4.53M | 3.42M | 2.70M |
| BasicAverageShares | 5.18M | 4.53M | 3.42M | 2.70M |
| DilutedEPS | -14.78 | -14.80 | -7.20 | -13.00 |
| BasicEPS | -14.78 | -14.80 | -7.20 | -13.00 |
| DilutedNIAvailtoComStockholders | -17.89M | -76.58M | -67.00M | -24.49M |
| NetIncomeCommonStockholders | -17.89M | -76.58M | -67.00M | -24.49M |
| NetIncome | -17.89M | -76.58M | -67.00M | -24.49M |
| NetIncomeIncludingNoncontrollingInterests | -17.89M | -76.58M | -67.00M | -24.49M |
| NetIncomeContinuousOperations | -17.89M | -76.58M | -67.00M | -24.49M |
| PretaxIncome | -17.89M | -76.58M | -67.00M | -24.49M |
| OtherIncomeExpense | 866.00K | -2.75M | -2.55M | -1.50M |
| OtherNonOperatingIncomeExpenses | -3.00K | -17.00K | -14.00K | -58.00K |
| SpecialIncomeCharges | -1.78M | -83.00K | -2.54M | -1.44M |
| GainOnSaleOfPPE | -246.00K | -83.00K | -2.54M | 0.00 |
| OtherSpecialCharges | 1.53M | 1.44M | ||
| GainOnSaleOfSecurity | 2.65M | -2.65M | ||
| NetNonOperatingInterestIncomeExpense | -6.81M | -8.00M | -1.22M | -1.70M |
| InterestExpenseNonOperating | 7.74M | 9.41M | 3.96M | 2.17M |
| InterestIncomeNonOperating | 929.00K | 1.42M | 2.74M | 476.00K |
| OperatingIncome | -11.94M | -65.84M | -63.22M | -21.30M |
| OperatingExpense | 44.08M | 70.66M | 67.60M | 29.60M |
| ResearchAndDevelopment | 8.86M | 11.84M | 20.30M | 12.20M |
| SellingGeneralAndAdministration | 35.22M | 58.82M | 47.30M | 17.41M |
| GeneralAndAdministrativeExpense | 17.41M | 26.98M | ||
| OtherGandA | 17.41M | 26.98M | ||
| GrossProfit | 32.14M | 4.83M | 4.38M | 8.31M |
| CostOfRevenue | 3.44M | 2.74M | 746.00K | 725.00K |
| TotalRevenue | 35.58M | 7.57M | 5.12M | 9.03M |
| OperatingRevenue | 35.58M | 7.57M | 5.12M | 9.03M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 10.51K | 10.51K | 10.51K | 10.51K |
| OrdinarySharesNumber | 17.18M | 9.18M | 4.24M | 4.11M |
| ShareIssued | 17.19M | 9.19M | 4.25M | 4.12M |
| NetDebt | 25.94M | |||
| TotalDebt | 1.63M | 45.94M | 45.51M | 1.53M |
| TangibleBookValue | 24.74M | -9.86M | 19.76M | 40.03M |
| InvestedCapital | 24.74M | 34.06M | 62.64M | 40.03M |
| WorkingCapital | 26.10M | 22.17M | 60.51M | 35.66M |
| NetTangibleAssets | 24.74M | -9.86M | 19.76M | 40.03M |
| CapitalLeaseObligations | 1.63M | 2.02M | 2.64M | 1.53M |
| CommonStockEquity | 24.74M | -9.86M | 19.76M | 40.03M |
| TotalCapitalization | 24.74M | 21.12M | 62.64M | 40.03M |
| TotalEquityGrossMinorityInterest | 24.74M | -9.86M | 19.76M | 40.03M |
| StockholdersEquity | 24.74M | -9.86M | 19.76M | 40.03M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -29.00K | ||
| OtherEquityAdjustments | -29.00K | |||
| TreasuryStock | 0.00 | 0.00 | 0.00 | 0.00 |
| RetainedEarnings | -324.91M | -307.03M | -230.45M | -163.45M |
| AdditionalPaidInCapital | 349.65M | 297.17M | 250.21M | 203.48M |
| CapitalStock | 2.00K | 1.00K | 4.00K | 4.00K |
| CommonStock | 2.00K | 1.00K | 4.00K | 4.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 22.39M | 63.99M | 61.83M | 4.69M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 5.95M | 34.98M | 44.81M | 1.23M |
| OtherNonCurrentLiabilities | 5.07M | |||
| DerivativeProductLiabilities | 0.00 | 2.65M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 885.00K | 32.33M | 44.81M | 1.23M |
| LongTermCapitalLeaseObligation | 885.00K | 1.35M | 1.94M | 1.23M |
| LongTermDebt | 30.98M | 42.87M | ||
| CurrentLiabilities | 16.44M | 29.01M | 17.02M | 3.46M |
| OtherCurrentLiabilities | 119.00K | 105.00K | 244.00K | |
| CurrentDeferredLiabilities | 782.00K | 0.00 | ||
| CurrentDeferredRevenue | 782.00K | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 746.00K | 13.61M | 700.00K | 297.00K |
| CurrentCapitalLeaseObligation | 746.00K | 667.00K | 700.00K | 297.00K |
| CurrentDebt | 12.94M | 41.69M | ||
| OtherCurrentBorrowings | 12.94M | 41.69M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.76M | 1.17M | 3.44M | 1.40M |
| CurrentProvisions | 8.56M | 10.32M | 5.36M | |
| PayablesAndAccruedExpenses | 4.46M | 3.81M | 7.29M | 1.76M |
| CurrentAccruedExpenses | 2.39M | 1.92M | 4.82M | 1.26M |
| InterestPayable | 0.00 | 250.00K | ||
| Payables | 2.07M | 1.90M | 2.46M | 507.00K |
| AccountsPayable | 2.07M | 1.90M | 2.46M | 507.00K |
| TotalAssets | 47.13M | 54.13M | 81.60M | 44.72M |
| TotalNonCurrentAssets | 4.59M | 2.96M | 4.07M | 5.61M |
| OtherNonCurrentAssets | 376.00K | 376.00K | 452.00K | 276.00K |
| NonCurrentDeferredAssets | 2.35M | 0.00 | ||
| NetPPE | 1.86M | 2.58M | 3.62M | 5.33M |
| AccumulatedDepreciation | -1.05M | -1.26M | -1.17M | -699.00K |
| GrossPPE | 2.91M | 3.84M | 4.79M | 6.03M |
| Leases | 54.00K | 54.00K | 54.00K | 54.00K |
| ConstructionInProgress | 0.00 | 2.54M | 2.73M | |
| OtherProperties | 1.11M | 1.15M | 1.41M | |
| MachineryFurnitureEquipment | 1.21M | 1.79M | 2.17M | 2.00M |
| BuildingsAndImprovements | 540.00K | 836.00K | 1.16M | 1.44M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 42.54M | 51.18M | 77.53M | 39.12M |
| OtherCurrentAssets | 2.80M | 2.31M | 2.54M | 4.36M |
| CurrentDeferredAssets | 1.96M | 0.00 | ||
| PrepaidAssets | 3.97M | |||
| Inventory | 2.24M | 2.46M | 1.02M | 0.00 |
| FinishedGoods | 478.00K | 717.00K | 115.00K | 0.00 |
| WorkInProcess | 784.00K | 664.00K | 487.00K | 0.00 |
| RawMaterials | 974.00K | 1.08M | 420.00K | 0.00 |
| Receivables | 5.40M | 77.00K | 4.42M | 487.00K |
| OtherReceivables | 137.00K | 29.00K | 168.00K | 99.00K |
| AccountsReceivable | 5.26M | 48.00K | 4.25M | 388.00K |
| CashCashEquivalentsAndShortTermInvestments | 30.15M | 46.33M | 69.55M | 34.27M |
| OtherShortTermInvestments | 0.00 | 54.60M | ||
| CashAndCashEquivalents | 30.15M | 46.33M | 69.55M | 34.27M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -17.63M | -60.95M | -38.94M | -18.95M |
| RepaymentOfDebt | -48.20M | -924.00K | -23.00K | -43.75M |
| IssuanceOfDebt | 0.00 | 0.00 | 44.10M | 0.00 |
| IssuanceOfCapitalStock | 50.07M | 42.50M | 30.30M | 26.90M |
| CapitalExpenditure | -27.00K | -362.00K | -302.00K | -883.00K |
| InterestPaidSupplementalData | 5.17M | 7.22M | 3.15M | 1.79M |
| EndCashPosition | 30.15M | 46.33M | 69.55M | 34.27M |
| BeginningCashPosition | 46.33M | 69.55M | 34.27M | 15.75M |
| ChangesInCash | -16.18M | -23.22M | 35.27M | 18.52M |
| FinancingCashFlow | 1.45M | 37.73M | 74.21M | -16.87M |
| CashFlowFromContinuingFinancingActivities | 1.45M | 37.73M | 74.21M | -16.87M |
| NetOtherFinancingCharges | -420.00K | -4.00M | -176.00K | -17.00K |
| ProceedsFromStockOptionExercised | 0.00 | 155.00K | 7.00K | 0.00 |
| NetCommonStockIssuance | 50.07M | 42.50M | 30.30M | 26.90M |
| CommonStockIssuance | 50.07M | 42.50M | 30.30M | 26.90M |
| NetIssuancePaymentsOfDebt | -48.20M | -924.00K | 44.08M | -43.75M |
| NetShortTermDebtIssuance | -43.75M | 4.97M | ||
| ShortTermDebtPayments | -43.75M | 0.00 | ||
| ShortTermDebtIssuance | 0.00 | 4.97M | ||
| NetLongTermDebtIssuance | -48.20M | -924.00K | 44.08M | -43.75M |
| LongTermDebtPayments | -48.20M | -924.00K | -23.00K | -43.75M |
| LongTermDebtIssuance | 0.00 | 0.00 | 44.10M | 0.00 |
| InvestingCashFlow | 0.00 | -19.00K | -362.00K | 54.04M |
| CashFlowFromContinuingInvestingActivities | 0.00 | -19.00K | -362.00K | 54.04M |
| NetOtherInvestingChanges | -180.00K | -201.00K | ||
| NetInvestmentPurchaseAndSale | 0.00 | 54.34M | 86.00K | |
| SaleOfInvestment | 0.00 | 59.01M | 69.00M | |
| PurchaseOfInvestment | 0.00 | -4.67M | -68.91M | |
| NetPPEPurchaseAndSale | 0.00 | -19.00K | -362.00K | -302.00K |
| SaleOfPPE | 0.00 | 8.00K | 0.00 | |
| PurchaseOfPPE | 0.00 | -27.00K | -362.00K | -302.00K |
| OperatingCashFlow | -17.63M | -60.93M | -38.58M | -18.65M |
| CashFlowFromContinuingOperatingActivities | -17.63M | -60.93M | -38.58M | -18.65M |
| ChangeInWorkingCapital | -6.25M | 2.03M | 9.86M | -1.80M |
| ChangeInOtherWorkingCapital | 782.00K | -500.00K | ||
| ChangeInOtherCurrentLiabilities | -315.00K | -322.00K | -291.00K | -264.00K |
| ChangeInPayablesAndAccruedExpense | -1.14M | -862.00K | 13.49M | -593.00K |
| ChangeInAccruedExpense | -1.31M | -294.00K | 11.29M | -255.00K |
| ChangeInPayable | 176.00K | -568.00K | 2.20M | -338.00K |
| ChangeInAccountPayable | 176.00K | -568.00K | 2.20M | -338.00K |
| ChangeInPrepaidAssets | -264.00K | -1.13M | 587.00K | -456.00K |
| ChangeInReceivables | -5.32M | 4.34M | -3.93M | -487.00K |
| ChangesInAccountReceivables | -5.21M | 4.20M | -3.86M | 0.00 |
| OtherNonCashItems | 3.28M | 2.21M | 810.00K | 389.00K |
| StockBasedCompensation | 3.32M | 7.16M | 14.38M | 4.99M |
| AssetImpairmentCharge | 0.00 | 255.00K | 0.00 | |
| AmortizationOfSecurities | 0.00 | 108.00K | 66.00K | |
| DepreciationAmortizationDepletion | 781.00K | 1.27M | 836.00K | 718.00K |
| DepreciationAndAmortization | 781.00K | 1.27M | 836.00K | 718.00K |
| Depreciation | 781.00K | 1.27M | 836.00K | 718.00K |
| OperatingGainsLosses | -869.00K | 2.73M | 2.54M | 1.44M |
| GainLossOnInvestmentSecurities | -2.65M | 2.65M | ||
| GainLossOnSaleOfPPE | 246.00K | 83.00K | 2.54M | 0.00 |
| NetIncomeFromContinuingOperations | -17.89M | -76.58M | -67.00M | -24.49M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VRCA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|